Business Wire

OR-RADISYS

26.2.2024 08:01:32 CET | Business Wire | Press release

Share
Radisys Unveils Engage Clarity to Enhance Phone Conversations for People Experiencing Hearing Loss

The World Health Organization estimates that 20% of the world’s population today suffers from some degree of hearing loss. This figure is expected to increase to an estimated 25% (nearly 2.5 billion) by 2050. Over time, individuals with hearing loss tend to stop socializing – leading to impacts on friends and family members as well as increasing the risk of other health issues, including a higher likelihood of dementia. Hearing difficulties are particularly challenging in phone conversations as telephony is not designed to cater to those with hearing loss, and visual cues like lip reading that can help overcome some hearing difficulties are absent.

Radisys® Corporation, a global leader of open telecom solutions, today announced the availability of Engage Clarity, a unique service that enhances the quality and comprehensibility of voice calls for people with hearing challenges. With the goal to significantly enhance their quality of life and interactions, a personalized and unique service profile is activated, enabling in-line, real-time enhancements that deliver a superior experience. Engage Clarity seamlessly integrates with telecom operators' communication networks, ensuring a smooth and user-friendly implementation experience without requiring any special applications and devices. The Engage Clarity is accessible via any device through mobile voice, fixed voice, or OTT/web communication service.

With Radisys’ Engage Clarity, MNOs have a unique opportunity to offer a fully personalized wellness solution to their subscribers and meet inclusivity and societal improvement objectives. With a suggested street price per month that is less than the cost of a cup of coffee, this unique solution enhances the quality of life and improves accessibility to services for people with hearing loss. The solution benefits can be extended to anyone in consumer and business calls.

With global leadership in media processing, Radisys is uniquely positioned to deliver the benefits of Engage Clarity through service providers. “The ability to ensure the voice clarity in conversations between grandparents and grandchildren, patients and doctors, businesses and their customers – regardless of the background noise - has broad benefits to users and operators,” said Al Balasco, Head of Digital Experiences and Applications Business, Radisys. “Voice is communication’s lowest common denominator, and ensuring the highest quality experience can be life-changing for those experiencing hearing challenges.”

Radisys’ Engage Clarity addresses a critical need for people with hearing difficulties during voice calls. Clinical trials revealed high levels of user satisfaction, with 90% of users finding speech clearer and easier to hear and 74% of users reporting that calls were less tiring, highlighting the positive impact of the service on the overall communication experience for everyone, not only people with hearing difficulties.

Hearing wellness is often neglected. Compared to examining their eyes annually, people rarely take a hearing test. Radisys’ Engage Clarity offers a unique entry point for MNOs to help people manage hearing wellness by suggesting regular check-ins with the Engage hearing profile creator when they change their handset or perhaps once a year.

Experience Engage Clarity at MWC Barcelona

Hear the difference Radisys’ Engage Clarity brings. Visit Radisys at MWC Barcelona, Stand 2D50 for a demonstration, or learn more by visiting www.engagedigital.ai/clarity. To schedule a meeting with Radisys’ experts, contact open@radisys.com.

About Radisys

Radisys is a global leader in open telecom solutions and services. Its disaggregated platforms and integration services leverage open reference architectures and standards combined with open software and hardware, enabling service providers to drive open digital transformation. Radisys offers an end-to-end solutions portfolio from digital endpoints to disaggregated and open access and core solutions, to immersive digital applications and engagement platforms. Its world-class and experienced network services organization delivers full lifecycle services to help service providers build and operate highly scalable and high-performance networks at optimum total cost of ownership. For more information, visit www.Radisys.com.

Radisys® is a registered trademark of Radisys. All other trademarks are the property of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240225545999/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release

Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d

Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release

Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release

Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L

Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release

New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel

HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 17:30:00 CEST | Press release

HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye